Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 843

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 843
---
 of interested party investments in the Company, as applicable) during the period that begins after the completion of this issuance and ends on October 30, 2021 (see Note 18f). The warrants’ value, USD $2,389 thousands, was determined according to the Black -Scholesmodel based on the following assumptions:

| Expected share price volatility (%)        |     | 74% – 75%    |
| Risk-free interest rate (%)                |     | 0.1%         |
| Share price USD $0.03 (NIS 0.1 p.v.) (USD) |     | 1.129 – 1.05 |

As of July 9, 2021, the receipt of the total Consideration according to the investment agreements was completed, at USD $6,859 thousand, and after deducting the issuance expenses, USD $346 thousand, the Company received a total of USD $6,513 thousand. On April 30, 2023, 3,930,876 non -marketableequity -basedSeries F warrants (B1 and B2) expired.

Annex G-34 KADIMASTEM LTD.
NOTES TO FINANCIAL STATEMENTS Note 18: — EQUITY (cont.) F.On October 21, 2021, the Company’s Board of Directors gave its approval, after receiving the approval of the audit committee, for a private investment in the Company in the aggregate amount of USD $2.94 million (NIS 9.45 million) by way of a private placement and the exercise of non -marketablewarrants (Series A). In accordance with the investment agreement, the 5 investors who had participated in the April 25, 2021, private placement led by Clover and Alpha Fund would exercise the Series A warrants they hold through an early exercise. In exchange for the fact that the investors would immediately exercise the Series A Warrants, in a total amount of USD $2.94, whose expiration date is July 31, 2022, and accordingly would inject an investment into the Company that totals USD $2.94 million, in return, they would be issued 2,158,783 Series C warrants, with an exercise price per warrant of USD $2 (NIS 7) until December 31, 2023. Until December 31, 2021, 1,466,087 non -marketableSeries A warrants were exercised, for which the